United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravachol (pravastatin sodium) is indicated to: in patients with clinically evident chd, pravachol is indicated to: pravachol is indicated: pravachol has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [see warnings and precautions (5.3) ]. atherosclerosis is a chronic process and discontinuation of lipid-lowering dru

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - pravastatin sodium, quantity: 80 mg - tablet, uncoated - excipient ingredients: povidone; croscarmellose sodium; iron oxide yellow; microcrystalline cellulose; magnesium stearate; lactose monohydrate; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; magnesium oxide; croscarmellose sodium; microcrystalline cellulose; povidone; lactose monohydrate - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indica

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; povidone; microcrystalline cellulose; lactose monohydrate; iron oxide yellow; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indica

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pravastatin sodium 10mg;  ;  ;   - tablet - 10 mg - active: pravastatin sodium 10mg       excipient: croscarmellose sodium iron oxide yellow lactose monohydrate magnesium oxide magnesium stearate microcrystalline cellulose povidone - 1. in hypercholesterolemic patients without clinically evident coronary heart disease, pravachol is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. 2. pravachol is indicated for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. 3. pravachol is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pravastatin sodium 20mg;  ;  ;   - tablet - 20 mg - active: pravastatin sodium 20mg       excipient: croscarmellose sodium iron oxide yellow lactose monohydrate magnesium oxide magnesium stearate microcrystalline cellulose povidone - 1. in hypercholesterolemic patients without clinically evident coronary heart disease, pravachol is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. 2. pravachol is indicated for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. 3. pravachol is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - pravastatin sodium 40mg;  ;  ;   - tablet - 40 mg - active: pravastatin sodium 40mg       excipient: croscarmellose sodium iron oxide yellow lactose monohydrate magnesium oxide magnesium stearate microcrystalline cellulose povidone - 1. in hypercholesterolemic patients without clinically evident coronary heart disease, pravachol is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. 2. pravachol is indicated for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. 3. pravachol is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - pravastatin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium oxide; magnesium stearate; povidone; lactose monohydrate; iron oxide yellow; microcrystalline cellulose - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysprotenemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. indications as at 20 august 1996: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia, (e.g. poorly controlled diabetes mellitus, hypothroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. indications as at 2 march 1999: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver d

Canada - English - Health Canada

bristol-myers squibb canada - pravastatin sodium - tablet - 10mg - pravastatin sodium 10mg - hmg-coa reductase inhibitors